



HCA Healthcare, Inc. (HCA)

Updated May 7th, 2025 by Samuel Smith

Key Metrics

Current Price:	\$361	5 Year CAGR Estimate:	10.8%	Market Cap:	\$89 B
Fair Value Price:	\$374	5 Year Growth Estimate:	9.4%	Ex-Dividend Date:	6/17/25 ¹
% Fair Value:	97%	5 Year Valuation Multiple Estimate:	0.7%	Dividend Payment Date:	6/31/25 ²
Dividend Yield:	0.8%	5 Year Price Target	\$585	Years Of Dividend Growth:	5
Dividend Risk Score:	C	Sector:	Health Care	Rating:	Hold

Overview & Current Events

HCA Healthcare, Inc., founded in 1968 and headquartered in Nashville, Tennessee, is one of the nation's leading providers of healthcare services. It owns and operates nearly 200 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics across 20 U.S. states and the United Kingdom. The company employs about 271,000 people, including 94,000 registered nurses and 38,000 active physicians.

On April 25, 2025, HCA Healthcare reported its financial results for the first quarter of 2025. The company achieved revenues of \$18.32 billion, a 5.7% increase from the \$17.34 billion reported in the same period of the previous year. Net income attributable to HCA Healthcare was \$1.61 billion, or \$6.45 per diluted share, surpassing analysts' expectations of \$5.76 per share and improving from \$5.93 per share a year ago. Adjusted EBITDA for the quarter was \$3.73 billion, up from \$3.35 billion in the first quarter of 2024. The growth was driven by a sustained increase in patient volumes, with same-facility admissions rising 2.6%, same-facility equivalent admissions increasing 2.8%, and emergency room visits up by 4%. However, outpatient surgeries declined by 2.1% year-over-year, a decrease partially attributed to the leap year in 2024 and seasonal factors. The company maintained a strong payer mix and reported that over 90% of its managed care contracts for 2025 are settled, providing revenue stability. Operating cash flows for the quarter were \$1.65 billion, compared to \$2.47 billion in the prior-year quarter. During the quarter, HCA repurchased 7.76 million shares of its common stock for \$2.5 billion and declared a quarterly cash dividend of \$0.72 per share, payable on June 30 to stockholders of record as of June 16, 2025. The company reaffirmed its full-year 2025 guidance, projecting revenues between \$72.80 billion and \$75.80 billion and earnings per share in the range of \$24.05 to \$25.85. Management expressed confidence in the company's performance and growth prospects, citing ongoing investments in expanding network and inpatient capacity to meet the rising demand for healthcare services.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$5.56	\$6.87	\$6.81	\$9.77	\$10.50	\$11.61	\$17.50	\$16.89	\$19.01	\$21.96	\$24.92	\$39.00
DPS	\$0.00	\$0.00	\$0.00	\$1.40	\$1.63	\$0.43	\$1.92	\$2.24	\$2.40	\$2.64	\$2.88	\$3.60
Shares	397.0	370.2	349.9	342.4	338.4	339.9	303.6	277.0	264.5	248.3	248.3	235.0

HCA Healthcare is positioned for strong growth over the next five years, with earnings per share expected to rise from \$24.92 to \$39, driven by expanding patient volumes, strategic acquisitions, and operational efficiencies. Dividends per share are projected to increase from \$2.88 to \$3.60, reflecting confidence in sustained cash flow generation. HCA's extensive hospital network, investments in technology, and focus on cost management should enhance profitability. While regulatory changes and labor costs pose risks, the company's scale, strong payer relationships, and demand for healthcare services position it well for continued revenue and earnings expansion, supporting shareholder returns.

¹ Estimate

² Estimate

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



HCA Healthcare, Inc. (HCA)

Updated May 7th, 2025 by Samuel Smith

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	13.1	10.2	11.3	11.0	11.9	10.4	12.1	12.9	13.7	15.3	14.5	15.0
Avg. Yld.	0.0%	0.0%	0.0%	1.3%	1.3%	0.4%	0.9%	1.0%	0.9%	0.8%	0.8%	0.6%

HCA is currently trading at a P/E ratio of 14.5, slightly above its 10-year historical average of 13.7 but above its long-term lows. The company's P/E has steadily expanded, reflecting investor confidence in its earnings stability and growth potential. The dividend yield of 0.8% remains low, as HCA prioritizes reinvestment and share buybacks over large dividend payouts. Over the next five years, if earnings continue growing steadily, the P/E ratio could range between 14-16, aligning with historical trends. However, if regulatory pressures or reimbursement challenges emerge, the multiple may stay closer to 12-14, limiting valuation expansion.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	0%	0%	0%	14%	16%	4%	11%	13%	13%	12%	12%	9%


HCA's competitive advantage lies in its extensive hospital network, scale, and operational efficiency, allowing it to negotiate favorable payer contracts and optimize costs. As the largest for-profit hospital operator in the U.S., it benefits from economies of scale and strong demand for healthcare services. During the Great Recession, HCA's earnings remained stable due to the non-discretionary nature of healthcare, though margin pressure was evident. The COVID-19 pandemic created short-term disruptions, but demand rebounded quickly as elective procedures resumed, demonstrating the company's resilience in economic downturns.

HCA maintains a healthy balance sheet with manageable debt and strong interest coverage, ensuring financial flexibility. The payout ratio has remained conservative, peaking at 16% in 2019 and stabilizing around 12% in recent years, reflecting the company's preference for reinvestment. With continued earnings growth, the payout could remain near 10-12%, ensuring dividend sustainability while allowing capital to be directed toward expansion and acquisitions. HCA's focus on cost control and strategic investments supports long-term shareholder value despite its modest yield.

Final Thoughts & Recommendation

Between its 0.8% dividend yield, 9.4% expected five-year EPS CAGR, and 0.7% expected five-year valuation multiple CAGR, we project a 10.8% annualized total return for HCA over the next half-decade, making it a Hold at the moment.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



HCA Healthcare, Inc. (HCA)

Updated May 7th, 2025 by Samuel Smith

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	39,678	41,490	43,614	46,677	51,336	51,533	58,752	60,233	64,968	70,603
Gross Profit	33,040	34,557	36,298	38,953	42,855	43,164	49,271	50,862	55,066	59,848
Gross Margin	83.3%	83.3%	83.2%	83.5%	83.5%	83.8%	83.9%	84.4%	84.8%	84.8%
SG&A Exp.	18,115	18,897	20,059	21,425	23,560	23,874	26,779	27,685	29,487	31,170
D&A Exp.	1,904	1,966	2,131	2,278	2,596	2,721	2,853	2,969	3,077	3,312
Operating Profit	5,965	6,198	6,057	6,642	7,218	7,262	9,678	9,053	9,627	10,547
Operating Margin	15.0%	14.9%	13.9%	14.2%	14.1%	14.1%	16.5%	15.0%	14.8%	14.9%
Net Profit	2,129	2,890	2,216	3,787	3,505	3,754	6,956	5,643	5,242	5,760
Net Margin	5.4%	7.0%	5.1%	8.1%	6.8%	7.3%	11.8%	9.4%	8.1%	8.2%
Free Cash Flow	2,359	2,893	2,411	3,188	3,444	6,397	5,382	4,127	4,687	5,639
Income Tax	1,261	1,378	1,638	946	1,099	1,043	2,112	1,746	1,615	1,866

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	32,744	33,758	36,593	39,207	45,058	47,490	50,742	52,438	56,211	59,513
Cash & Equivalents	741	646	732	502	621	1,793	1,451	908	935	1,933
Accounts Receivable	5,889	5,826	6,501	6,789	7,380	7,051	8,095	8,891	9,958	10,751
Inventories	1,439	1,503	1,573	1,732	1,849	2,025	1,986	2,068	2,021	1,738
Goodwill & Int. Ass.	6,731	6,704	7,394	7,953	8,269	8,578	9,540	9,653	9,945	10,093
Total Liabilities	38,790	39,391	41,588	42,125	45,623	44,598	49,253	52,511	55,151	58,958
Accounts Payable	2,170	2,318	2,606	2,577	2,905	3,535	4,111	4,239	4,233	4,276
Long-Term Debt	30,488	31,376	33,058	32,821	33,722	31,004	34,579	38,084	39,593	43,031
Shareholder's Equity	(7,599)	(7,302)	(6,806)	(4,950)	(2,808)	572	(933)	(2,767)	(1,774)	(2,499)
LTD/E Ratio	(4.01)	(4.30)	(4.86)	(6.63)	(12.01)	54.20	(37.06)	(13.76)	(22.32)	(17.22)

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	6.7%	8.7%	6.3%	10.0%	8.3%	8.1%	14.2%	10.9%	9.6%	10.0%
Return on Equity						322.6%	317.6%	797.0%	1062%	713.3%
ROIC	9.0%	11.5%	8.2%	13.1%	11.1%	11.2%	19.9%	15.2%	13.3%	13.7%
Shares Out.	397.0	370.2	349.9	342.4	338.4	339.9	303.6	277.0	264.5	248.3
Revenue/Share	92.98	104.81	117.17	131.37	147.42	149.98	178.71	204.41	235.04	269.68
FCF/Share	5.53	7.31	6.48	8.97	9.89	18.62	16.37	14.01	16.96	21.54

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.